ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
TELIX PHARMACEUTICALS LTD
9.200
+0.170
1.88%
成交量:
197.69万
成交额:
1,813.94万
市值:
31.16亿
市盈率:
-310.01
高:
9.290
开:
9.220
低:
9.030
收:
9.030
52周最高:
31.970
52周最低:
8.260
股本:
3.39亿
流通股本:
2.75亿
量比:
0.47
换手率:
0.72%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.030
每股收益(LYR):
-0.030
净资产收益率:
-1.85%
总资产收益率:
1.15%
市净率:
5.33
市盈率(LYR):
-310.00
数据加载中...
总览
公司
新闻资讯
公告
Telix实现2025财年营收8.04亿美元(12亿澳元)目标,Gozellix上市加速增长
美股速递
·
01/20
BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨
路透中文
·
01/20
精准医疗投资组合更新:Illuccix中国三期研究及Tlx101-Cdx和Tlx250-Cdx FDA重新提交
美股速递
·
2025/12/22
Thor Medical与Telix Pharmaceuticals签署战略供应协议,提供铥228
投资观察
·
2025/11/20
Holzer & Holzer - 起诉指控被告对Telix的业务、运营等做出实质性虚假陈述
美股速递
·
2025/11/13
美国 FDA 要求提供更多有关泰利克斯制药公司肾癌诊断药物的信息
路透中文
·
2025/08/28
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/TLX.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":9.2,"timestamp":1771996320000,"preClose":9.03,"halted":0,"volume":1976919,"delay":0,"changeRate":0.018826135105204866,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.029676720652043968,"marketStatus":"已收盘","change":0.17,"latestTime":"02-25 16:12:00 AEDT","open":9.22,"high":9.29,"low":9.03,"amount":18139391,"amplitude":0.028793,"askPrice":9.2,"askSize":15183,"bidPrice":9.14,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-0.029676720652043968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1772060400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":9.03,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0.467739,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"1.15%","roe":"-1.85%","lyrEps":-0.029677,"volumeRatio":0.467739,"shares":338721355,"dividePrice":0,"high":9.29,"amplitude":0.028793,"preClose":9.03,"low":9.03,"week52Low":8.26,"pbRate":"5.33","psRate":"2.76","week52High":31.97,"institutionHeld":0,"latestPrice":9.2,"committee":-0.961248,"eps":-0.029676720652043968,"divideRate":0,"volume":1976919,"delay":0,"ttmEps":-0.029676720652043968,"open":9.22,"prevYearClose":11.2,"prevWeekClose":10.43,"prevMonthClose":10.55,"prevQuarterClose":11.2,"fiveDayClose":8.88,"twentyDayClose":11.65,"sixtyDayClose":15.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167408007","title":"Telix实现2025财年营收8.04亿美元(12亿澳元)目标,Gozellix上市加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1167408007","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167408007?lang=zh_cn&edition=fundamental","pubTime":"2026-01-20 20:07","pubTimestamp":1768910869,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd宣布达成2025财年业绩指引,实现营收8.04亿美元。公司同时推出新型放射性药物Gozellix,标志着其肿瘤靶向治疗产品线的重大拓展。这一突破性进展不仅巩固了Telix在核医学领域的领先地位,更为全球癌症患者提供了更精准的治疗选择。随着Gozellix的正式商业化,Telix将同步启动全球市场推广计划。Telix首席执行官表示,此次双里程碑的达成得益于公司持续的技术创新与全球化战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2604055151","title":"BUZZ-澳大利亚泰利克斯制药公司因中国接受新药申请而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2604055151","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604055151?lang=zh_cn&edition=fundamental","pubTime":"2026-01-20 08:39","pubTimestamp":1768869597,"startTime":"0","endTime":"0","summary":"1月20日 - ** 澳大利亚泰利克斯制药公司TLX.AX股价上涨6.3%至11.99澳元,创下近两个月来最大盘中涨幅。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4S3YL01L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNLX","BK1191","TLX.AU","BK4157","BK7067","00512"],"gpt_icon":0},{"id":"1170607192","title":"精准医疗投资组合更新:Illuccix中国三期研究及Tlx101-Cdx和Tlx250-Cdx FDA重新提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1170607192","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170607192?lang=zh_cn&edition=fundamental","pubTime":"2025-12-22 05:40","pubTimestamp":1766353209,"startTime":"0","endTime":"0","summary":"精准医疗投资组合更新:Illuccix中国三期研究及Tlx101-Cdx和Tlx250-Cdx FDA重新提交","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"1108683421","title":"Thor Medical与Telix Pharmaceuticals签署战略供应协议,提供铥228","url":"https://stock-news.laohu8.com/highlight/detail?id=1108683421","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108683421?lang=zh_cn&edition=fundamental","pubTime":"2025-11-20 00:51","pubTimestamp":1763571104,"startTime":"0","endTime":"0","summary":"11月6日 - Thor Medical ASA宣布与Telix Pharmaceuticals达成战略供应协议,将在未来五年内向Telix供应铥228。从2026年第三季度起,铥228将从AlphaOne基地开始供给。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"1102089575","title":"Holzer & Holzer - 起诉指控被告对Telix的业务、运营等做出实质性虚假陈述","url":"https://stock-news.laohu8.com/highlight/detail?id=1102089575","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102089575?lang=zh_cn&edition=fundamental","pubTime":"2025-11-13 00:15","pubTimestamp":1762964112,"startTime":"0","endTime":"0","summary":"Holzer & Holzer - 起诉指控被告对Telix的业务、运营等做出实质性虚假陈述","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2562377000","title":"美国 FDA 要求提供更多有关泰利克斯制药公司肾癌诊断药物的信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2562377000","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562377000?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 09:52","pubTimestamp":1756345952,"startTime":"0","endTime":"0","summary":"美国 FDA 要求提供更多有关泰利克斯制药公司肾癌诊断药物的信息路透8月28日 - 澳大利亚癌症诊断公司Telix Pharmaceuticals TLX.AX周四表示,美国食品和药物管理局要求Telix Pharmaceuticals TLX.AX就其检测一种肾癌的诊断药物申请提供更多数据。美国药品监管机构指出了该公司在生产和供应链流程方面存在的缺陷,并要求该公司提供更多数据,以证明扩大规模后的商业生产流程与临床试验中使用的流程具有可比性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nL4S3UK04L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}